<DOC>
	<DOC>NCT00104234</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.</brief_summary>
	<brief_title>Study of rhASB in Patients With Mucopolysaccharidosis VI</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Patient consent Patient must have successfully completed study ASB0305, including having received at least 20 of 24 scheduled weekly infusions and having missed no more then two consecutive infusions If female of childbearing potential, patient must have a negative pregnancy test Pregnant or lactating patient Patient has received an investigational drug within 30 days prior to study enrollment Patient is unwilling or unable to travel to the primary site for periodic assessments</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>